← Back to Home

Another Later-Line Treatment Option for ALK-Positive Lung Cancer: FDA Grants Accelerated Approval to neladalkib

Patients with advanced lung cancer who have received specific ALK-targeted therapies now have another treatment option in the United States. Neladalkib demonstrated tumor shrinkage and intracranial responses in a single-arm trial, but whether it extends survival and how best to sequence treatment still require more complete evidence.

By SURL BioNews

For patients with ALK-positive lung cancer who have already received targeted therapy, further disease progression means finding another option that can control the tumor. On November 17, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to neladalkib (brand name Nelkarmi), adding a treatment pathway for patients with advanced disease who meet specific prior-treatment criteria. The decision was based on tumor response data, which do not yet establish that the drug extends life.

The approval applies to adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have received one of two treatment regimens in the unresectable locally advanced or metastatic setting: only one prior ALK tyrosine kinase inhibitor, alectinib; or at least two ALK inhibitors and platinum-containing chemotherapy. GSK's announcement noted that approval came ahead of the originally scheduled November 27 review target date; it does not make the drug available to all patients with lung cancer who have previously received targeted therapy.

ALKOVE-1, which supported the approval, is a multicenter, open-label, single-arm phase 1/2 trial. This efficacy analysis included 222 patients. By blinded independent central review, the objective response rate was 49% among the 67 patients who had previously received only alectinib, and 32% among the 155 patients who had received at least two ALK inhibitors and platinum-containing chemotherapy. Among patients who responded in each group, 52% and 51%, respectively, had responses lasting at least one year. The denominators for these percentages were responders, not all trial participants.

Control of brain lesions is another important aspect of the drug's evaluation. According to data released by GSK, among patients with measurable central nervous system metastases before treatment, intracranial response rates in the two groups were 55% (11 of 20 patients) and 26% (14 of 53 patients), respectively. The results show that brain tumors shrank in some patients, but the samples were limited, and these findings cannot be directly translated into effects on preventing brain metastases or achieving long-term control.

Differences in treatment history may also affect how response figures are interpreted. Targeted Oncology separately summarized a previously published efficacy analysis involving 253 patients: the response rate was 26% among those who had received lorlatinib and 46% among those who had not. This was not the same population as the 222-patient analysis supporting the current approval, and the data should not be used interchangeably. The two subgroups were also not randomly assigned, so these findings cannot establish which treatment sequence is better.

Safety also affects whether patients can continue taking the drug. FDA-listed warnings cover hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity. Common adverse reactions include hepatotoxicity, musculoskeletal pain, constipation, altered taste, peripheral neuropathy, edema, and fatigue. GSK stated that 5% of patients permanently discontinued treatment because of adverse reactions, most commonly hepatotoxicity.

Accelerated approval gives eligible patients earlier access to the drug, while verification of its clinical benefit must continue. ALKOVE-1 has no control group and therefore cannot directly answer whether neladalkib delays progression or extends overall survival compared with other therapies. GSK noted that the drug is also being evaluated in the phase 3 ALKAZAR trial in patients who have not received an ALK inhibitor. That study explores its role in an earlier line of treatment, and the current later-line approval results cannot be directly extrapolated to that setting.

References

  1. FDA
  2. GSK
  3. Targeted Oncology